Evidence map›Paper›PMID 35223668›Full record

ReviewClinical and experimental vaccine research2022

COVID-19 vaccines development in Africa: a review of current situation and existing challenges of vaccine production.

Emmanuel Lamptey, Ephraim Kumi Senkyire, Dooshima Aki Benita, Evans Osei Boakye

Open access · diamondAbstract readReview
In one paragraph

Review in Clinical and experimental vaccine research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Emmanuel LampteyInstitute of Life and Earth Sciences (Including Health and Agriculture), Pan African University, University of Ibadan, Oyo, Nigeria.ORCID https://orcid.org/0000-0002-7822-7593
Ephraim Kumi SenkyireGa-West Municipal Hospital, Ghana Health Service, Amasaman, Ghana.ORCID https://orcid.org/0000-0003-0789-701X
Dooshima Aki BenitaDepartment of Psychology, Benue State University, Makurdi, Nigeria.ORCID https://orcid.org/0000-0001-5393-4411
Evans Osei BoakyeDepartment of Social Work, University of Ghana, Accra, Ghana.ORCID https://orcid.org/0000-0002-0737-5126
Benue State University · NGGhana Health Service · GHLead City University · NGUniversity of Ghana · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the development of the coronavirus disease 2019 (COVID-19) vaccines and the launching of vaccination, the World Health Organization has reported that the African Continent is lagging in the race to vaccinate its population against the deadly virus. The Continent has received a limited number of vaccines, implying that vaccine production needs to be scaled up in Africa. In this review, we summarize the current situation concerning COVID-19 vaccine development in Africa, progress made, challenges faced in vaccine development over the years and potential strategies that will harness vaccine production success.

Indexed as

AfricaBarriersCOVID-19 vaccinesDevelopment

Identifiers

PMID35223668
PMCPMC8844666
OpenAlexW4212917771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.